Pharmaceuticals

Patent Pain Belts Barr

 

Shares of Barr Pharmaceuticals(BRL) dropped 9% in heavy trading Friday after the company said its oral contraceptive Seasonale would probably lose patent protection in September.

Although the company expressed disappointment, Barr has been hinting at its concerns to Wall Street. The company is pressing ahead with Seasonique, a follow-up oral contraceptive that will have greater patent protection. Last week, Barr predicted the Food and Drug Administration would approve the product this quarter.

Last month, Barr withdrew its application to the FDA for Seasonale Lo, a lower-dose version of Seasonale, saying it would probably need to conduct another expensive, time-consuming clinical trial to secure FDA approval. Both Seasonale and Seasonique enable women to reduce menstrual periods to quarterly from monthly.

By late morning, the stock was down $4.61 to $49.03. The price fell as low as $47.69. Trading volume of 1.7 million shares had already topped the average daily trade for the past three months of 1.22 million.

Barr said Friday it had received a "non-final rejection" notice from the Patent and Trademark Office relating to its effort to have one Seasonale patent reissued. This notice allows a company three months to respond to the patent office, which would then review the company's comments. Barr said it would be "unlikely, given the timing, that the patent in question could be reissued" prior to the Sept. 5 patent expiration date.

"While we are disappointed in the determination by the [patent office], we intend to fully review all options available to protect our patentable invention, and will respond to the non-final rejection as quickly as possible," said Bruce L. Downey, Barr's chairman and CEO.

Barr asked the patent office to reissue one Seasonale patent in July 2004, a month after Watson Pharmaceuticals (WPI) had filed a patent challenge, saying the Seasonale patent is invalid and unenforceable. A few days ago, Watson reported it had received tentative approval from the FDA for Seasonale, pending expiration of the patent.

TheStreet Premium Services

Jim Cramer
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
OptionsProfits
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn More
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
Dow Jones S&P 500 NASDAQ 10-Year Note
12,419.86 1,313.32 2,837.36 16.25
Oil *
103.00
DOWN
160.83
DOWN
19.10
DOWN
33.63
DOWN
1.06
10 Yr
1.62%
SPDR Gold
151.91
-1.28%
-1.43%
-1.17%
-6.12%
Data delayed 20 minutes

Top Stories and Tools

Articles From

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

We respect your privacy.
Podcasts

Connect with TheStreet